Insider Purchases: Inside the Buy
Tag: Wall Street
🌐 Globant (GLOB): The AI Infrastructure Tollbooth Trading at 7x Earnings
Globant (NYSE: GLOB) may be one of the most intriguing AI-related value plays on the market. Trading 87% below its peak, the company combines a growing AI-native services platform, accelerating cash flow, aggressive share buybacks, institutional ownership above 100% of float, and a historic first insider purchase from former Hong Kong Exchange CEO Alejandro Aguzin. Is Wall Street missing the story?
🏗️ AECOM (ACM): The $26 Billion Backlog Infrastructure Giant Trading at 12x Earnings
AECOM (NYSE: ACM) may be one of the most misunderstood infrastructure stocks in the market. With a record $26.2 billion backlog, insider buying from top executives, and a surprisingly cheap valuation, this engineering and consulting powerhouse could be quietly laying the foundation for substantial long-term upside.
🚪 Fortune Brands (FBIN): Activist Capital Just Kicked the Door Open
Fortune Brands Innovations (FBIN) is under pressure from weak housing demand, shrinking profits, and leadership uncertainty. But while Wall Street hesitates, activist investor Ed Garden just made a massive $13.6 million insider purchase. Is this a value trap… or a smart-home turnaround hiding in plain sight?
🥚 Vital Farms (VITL): The Great Egg Glut of 2026
Vital Farms stock has been absolutely scrambled by the 2026 egg glut, plunging more than 80% from its highs as profitability collapsed and short sellers flooded the farm. But coordinated insider buying, a debt-free balance sheet, and extreme institutional ownership suggest the setup may be far more explosive than the market currently realizes.
CHRW 2026: The “Karaoke Crash” and the Many Insiders “Buy-The-Dips”
A tiny “AI logistics” headline sparked a selloff in C.H. Robinson (CHRW). Insiders responded by buying. Is this a fear-driven dip or a signal that Lean AI is turning logistics into a margin machine?
Progress Software CEO Buys In — Maybe It’s More Than Just... Progress?
Progress Software's CEO and a director are buying shares, signaling confidence as the company posts strong earnings and raises guidance. With institutional investors owning over 121% of the float, is this under-the-radar compounder set for a rerating?
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
💼 The Godman Sachs Group, Inc. (GS): Where Wall Street Power Lunches with Olympus 🍽️📈
With soaring Q1 profits, billions returned to shareholders, and insiders buying in, Goldman Sachs is flexing its Wall Street muscle. From record M&A rankings to a $40B buyback plan, find out why GS might be the most solid financial play in your portfolio (and possibly Olympus). ⚖️💰